Literature DB >> 23313617

Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Janny Westdijk1, Patrick Koedam, Mario Barro, Benjamin P Steil, Nicolas Collin, Thomas S Vedvick, Wilfried A M Bakker, Peter van der Ley, Gideon Kersten.   

Abstract

Six different adjuvants, each in combination with inactivated polio vaccine (IPV) produced with attenuated Sabin strains (sIPV), were evaluated for their ability to enhance virus neutralizing antibody titres (VNTs) in the rat potency model. The increase of VNTs was on average 3-, 15-, 24-fold with adjuvants after one immunization (serotypes 1, 2, and 3, respectively). Also after a boost immunization the VNTs of adjuvanted sIPV were on average another 7-20-27 times higher than after two inoculations of sIPV without adjuvant. The results indicate that it is feasible to increase the potency of inactivated polio vaccines by using adjuvants.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23313617      PMCID： PMC3570672          DOI： 10.1016/j.vaccine.2012.12.076

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  30 in total

1.  Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions.

Authors:  Susan L Baldwin; Christopher B Fox; Mark A Pallansch; Rhea N Coler; Steven G Reed; Martin Friede
Journal:  Vaccine       Date:  2010-12-04       Impact factor: 3.641

Review 2.  Combination adjuvants: the next generation of adjuvants?

Authors:  George Mutwiri; Volker Gerdts; Sylvia van Drunen Littel-van den Hurk; Gael Auray; Nelson Eng; Srinivas Garlapati; Lorne A Babiuk; Andrew Potter
Journal:  Expert Rev Vaccines       Date:  2011-01       Impact factor: 5.217

Review 3.  The Vaccine Formulation Laboratory: a platform for access to adjuvants.

Authors:  Nicolas Collin; Patrice M Dubois
Journal:  Vaccine       Date:  2011-07-01       Impact factor: 3.641

4.  Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.

Authors:  Wilfried A M Bakker; Yvonne E Thomassen; Aart G van't Oever; Janny Westdijk; Monique G C T van Oijen; Lars C Sundermann; Peter van't Veld; Eelco Sleeman; Fred W van Nimwegen; Ahd Hamidi; Gideon F A Kersten; Nico van den Heuvel; Jan T Hendriks; Leo A van der Pol
Journal:  Vaccine       Date:  2011-06-07       Impact factor: 3.641

5.  Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization.

Authors:  Daniel R Tonkin; Patricia Jorquera; Tracie Todd; Clayton W Beard; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

6.  Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

7.  Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  AAPS PharmSciTech       Date:  2012-03-14       Impact factor: 3.246

8.  Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions.

Authors:  Christopher B Fox; Susan Lin; Sandra J Sivananthan; Timothy S Dutill; Kristen T Forseth; Steven G Reed; Thomas S Vedvick
Journal:  Pharm Dev Technol       Date:  2010-06-16       Impact factor: 3.133

9.  Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.

Authors:  Janny Westdijk; Debbie Brugmans; Javier Martin; Aart van't Oever; Wilfried A M Bakker; Lonneke Levels; Gideon Kersten
Journal:  Vaccine       Date:  2011-03-11       Impact factor: 3.641

10.  CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.

Authors:  Chunting Yang; Huiying Shi; Jun Zhou; Yanwen Liang; Honglin Xu
Journal:  Vaccine       Date:  2009-09-01       Impact factor: 3.641
View more
  15 in total

1.  H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferrets.

Authors:  Jørgen de Jonge; Harry van Dijken; Femke de Heij; Sanne Spijkers; Justin Mouthaan; Rineke de Jong; Paul Roholl; Eduardo Alfredo Adami; Milena Apetito Akamatsu; Paulo Lee Ho; Livia Brunner; Nicolas Collin; Martin Friede; José A Ferreira; Willem Luytjes
Journal:  NPJ Vaccines       Date:  2020-05-11       Impact factor: 7.344

2.  A mucosal adjuvant for the inactivated poliovirus vaccine.

Authors:  Benjamin P Steil; Patricia Jorquera; Janny Westdijk; Wilfried A M Bakker; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2013-12-13       Impact factor: 3.641

3.  Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.

Authors:  Hung-Chun Liao; Wan-Ling Wu; Chen-Yi Chiang; Min-Syuan Huang; Kuan-Yin Shen; Yu-Ling Huang; Suh-Chin Wu; Ching-Len Liao; Hsin-Wei Chen; Shih-Jen Liu
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

4.  Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats.

Authors:  Koen van der Maaden; Sebastiaan J Trietsch; Heleen Kraan; Eleni Maria Varypataki; Stefan Romeijn; Raphäel Zwier; Heiko J van der Linden; Gideon Kersten; Thomas Hankemeier; Wim Jiskoot; Joke Bouwstra
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

5.  Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles.

Authors:  Pim Schipper; Koen van der Maaden; Stefan Romeijn; Cees Oomens; Gideon Kersten; Wim Jiskoot; Joke Bouwstra
Journal:  Pharm Res       Date:  2016-06-17       Impact factor: 4.200

6.  Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

Authors:  Jes Dietrich; Lars Vibe Andreasen; Peter Andersen; Else Marie Agger
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

7.  Development of thermostable lyophilized inactivated polio vaccine.

Authors:  Heleen Kraan; Paul van Herpen; Gideon Kersten; Jean-Pierre Amorij
Journal:  Pharm Res       Date:  2014-04-24       Impact factor: 4.200

8.  Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.

Authors:  Jessica A White; Jeremy S Blum; Nancy A Hosken; Joshua O Marshak; Lauren Duncan; Changcheng Zhu; Elizabeth B Norton; John D Clements; David M Koelle; Dexiang Chen; William C Weldon; M Steven Oberste; Manjari Lal
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.

Authors:  Yvonne E Thomassen; Aart G van 't Oever; Monique G C T van Oijen; René H Wijffels; Leo A van der Pol; Wilfried A M Bakker
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

10.  Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies.

Authors:  Sonia Resik; Alina Tejeda; Magile Fonseca; Carolyn Sein; Lai Heng Hung; Yenisleidys Martinez; Manuel Diaz; Hiromasa Okayasu; Roland W Sutter
Journal:  Trials Vaccinol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.